Literature DB >> 21824458

Mother-infant antidepressant concentrations, maternal depression, and perinatal events.

Dorothy Sit1, James M Perel, Stephen R Wisniewski, Joseph C Helsel, James F Luther, Katherine L Wisner.   

Abstract

OBJECTIVE: The authors explored the relationship of cord-maternal antidepressant concentration ratios and maternal depression with perinatal events and preterm birth.
METHOD: The investigators examined 21 mother-infant pairs that had antidepressant exposure during pregnancy. The antidepressants included serotonin reuptake inhibitors (SRIs) and nortriptyline (a norepinephrine inhibitor and mild SRI). The mothers were evaluated with the Structured Clinical Interview for DSM-IV. Depression ratings were repeated at 20, 30, and 36 weeks' pregnancy. At delivery, investigators assessed cord and maternal antidepressant concentrations, neonatal outcomes on the Peripartum Events Scale (PES), and gestational weeks at birth. The investigators performed this study at the Women's Behavioral HealthCARE Program, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pennsylvania, from April 2003 until September 2006.
RESULTS: Mean ± SD cord-to-maternal concentration ratios were 0.52 ± 0.35 (range, 0.00-1.64) for the parent drug and 0.54 ± 0.17 (range, 0.28-0.79) for the metabolite. Nine of 21 mothers (43%) had a major depressive episode. From examining the maximum depression ratings, the mean ± SD Structured Interview Guide for the Hamilton Depression Rating Scale, Atypical Depression Symptoms Version score was 16.0 ± 7.6. One third (7/21) of infants had at least 1 perinatal event (PES ≥ 1). The frequency of deliveries complicated by any perinatal event was similar in depressed and nondepressed mothers. There was no significant association between perinatal events and cord-to-maternal antidepressant concentration ratios or maternal depression levels. Exposure to short half-life antidepressants compared to fluoxetine resulted in more perinatal events (7/16 = 44% vs 0/5 = 0%; P = .06). Fourteen percent (3/21) of infants were preterm. Preterm birth was not associated with cord-to-maternal metabolite concentration ratios, depression levels, or exposure to fluoxetine.
CONCLUSIONS: Antidepressant-exposed infants experienced a limited number of transient perinatal events. No association between cord-maternal concentration ratios or maternal depression and perinatal events could be identified. Contrary to other reports, we detected no increased risk for perinatal events with fluoxetine therapy compared to the short half-life antidepressants. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00279370. © Copyright 2011 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21824458      PMCID: PMC3158589          DOI: 10.4088/JCP.10m06461

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  57 in total

1.  A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health.

Authors:  W Warburton; C Hertzman; T F Oberlander
Journal:  Acta Psychiatr Scand       Date:  2009-10-30       Impact factor: 6.392

2.  Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors.

Authors:  Karen L Wilson; Craig M Zelig; John P Harvey; Bethany S Cunningham; Brad M Dolinsky; Peter G Napolitano
Journal:  Am J Perinatol       Date:  2010-07-06       Impact factor: 1.862

3.  Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.

Authors:  Dorothy Sit; James M Perel; James F Luther; Stephen R Wisniewski; Joseph C Helsel; Katherine L Wisner
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

4.  Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes.

Authors:  Katherine L Wisner; Dorothy K Y Sit; Barbara H Hanusa; Eydie L Moses-Kolko; Debra L Bogen; Diane F Hunker; James M Perel; Sonya Jones-Ivy; Lisa M Bodnar; Lynn T Singer
Journal:  Am J Psychiatry       Date:  2009-03-16       Impact factor: 18.112

5.  Maternal use of venlafaxine near term: correlation between neonatal effects and plasma concentrations.

Authors:  Nina Boucher; Gideon Koren; Louise Beaulac-Baillargeon
Journal:  Ther Drug Monit       Date:  2009-06       Impact factor: 3.681

6.  Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.

Authors:  J Rampono; K Simmer; K F Ilett; L P Hackett; D A Doherty; R Elliot; C H Kok; A Coenen; T Forman
Journal:  Pharmacopsychiatry       Date:  2009-05-18       Impact factor: 5.788

7.  Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.

Authors:  Christina L Wichman; Katherine M Moore; Tara R Lang; Jennifer L St Sauver; Robert H Heise; William J Watson
Journal:  Mayo Clin Proc       Date:  2009       Impact factor: 7.616

8.  Serotonin discontinuation syndrome following in utero exposure to antidepressant medication: prospective controlled study.

Authors:  Megan Galbally; Andrew J Lewis; Jarrad Lum; Anne Buist
Journal:  Aust N Z J Psychiatry       Date:  2009-09       Impact factor: 5.744

9.  Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.

Authors:  M Reis; B Källén
Journal:  Psychol Med       Date:  2010-01-05       Impact factor: 7.723

10.  Risk of stillbirth and neonatal death linked with maternal mental illness: a national cohort study.

Authors:  S King-Hele; R T Webb; P B Mortensen; L Appleby; A Pickles; K M Abel
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-11-10       Impact factor: 5.747

View more
  17 in total

Review 1.  Annual Research Review: Maternal antidepressant use during pregnancy and offspring neurodevelopmental problems - a critical review and recommendations for future research.

Authors:  Ayesha C Sujan; A Sara Öberg; Patrick D Quinn; Brian M D'Onofrio
Journal:  J Child Psychol Psychiatry       Date:  2018-12-05       Impact factor: 8.982

Review 2.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

3.  Neonatal infant EEG bursts are altered by prenatal maternal depression and serotonin selective reuptake inhibitor use.

Authors:  P G Grieve; W P Fifer; N P Cousy; C E Monk; R I Stark; J A Gingrich; M M Myers
Journal:  Clin Neurophysiol       Date:  2019-09-03       Impact factor: 3.708

Review 4.  Prenatal depression and adverse birth outcomes: an updated systematic review.

Authors:  Eynav Elgavish Accortt; Alyssa C D Cheadle; Christine Dunkel Schetter
Journal:  Matern Child Health J       Date:  2015-06

Review 5.  Placental transfer of antidepressant medications: implications for postnatal adaptation syndrome.

Authors:  Grace Ewing; Yekaterina Tatarchuk; Dina Appleby; Nadav Schwartz; Deborah Kim
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

6.  Pharmacokinetics of fluoxetine in pregnant baboons (Papio spp.).

Authors:  Rivka L Shoulson; Raymond L Stark; Marianne Garland
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-11       Impact factor: 1.232

Review 7.  Drugs in pregnancy: Pharmacologic and physiologic changes that affect clinical care.

Authors:  Emily A Pinheiro; Catherine S Stika
Journal:  Semin Perinatol       Date:  2020-01-25       Impact factor: 3.300

Review 8.  A common clinical conundrum: Antidepressant treatment of depression in pregnant women.

Authors:  Gabrielle A Mesches; Katherine L Wisner; Hannah K Betcher
Journal:  Semin Perinatol       Date:  2020-01-25       Impact factor: 3.300

9.  Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: A systematic review & combined analysis.

Authors:  Georgios Schoretsanitis; Andreas A Westin; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Olav Spigset
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2021-01-02       Impact factor: 5.067

10.  Placental serotonin: implications for the developmental effects of SSRIs and maternal depression.

Authors:  Juan C Velasquez; Nick Goeden; Alexandre Bonnin
Journal:  Front Cell Neurosci       Date:  2013-04-23       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.